Taking a daily multivitamin may slow down biological ageing
Digest more
Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer Clinical trials frequently include multiple end points that mature at different times.
The COSMOS trial found that a daily multivitamin delayed biological aging by 2.7 to 5.1 months, and that this effect was more apparent in older adults who are already experiencing accelerated aging.
Abrocitinib shows sustained improvement in atopic dermatitis symptoms over two years with an acceptable safety profile.
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease In this phase II, prospective randomized ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as ...
Clinician and patient responses for cutaneous cGVHD were associated with higher nonrelapse mortality when comparing worsening vs improved disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results